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Abstract
Programmed cell death (PCD) pathways are genetically programmed mechanisms that
can trigger the cell to die or commit “cell suicide”. There are three major forms of pro‐
grammed cell death that are now recognized: apoptosis (type I), autophagy (type II) and
necrotic cell death or necroptosis (type III). While these cell death processes were once
thought to occupy discrete cell states, evidence suggests that apoptosis, autophagy and
necrosis are often regulated by similar pathways and share initiator and effector mole‐
cules and some subcellular compartments indicating that crosstalk exists between these
three main forms of cell death pathways, resulting in a balanced interplay by which the
cell decides its fate. PCD pathways have important roles in many cellular processes such
as development and oncogenic transformation, but PCD pathways also play important
roles in host defense and elimination of pathogens. Toxoplasma gondii is a microbial patho‐
gen for which programmed cell death pathways are a key part of the host defense. T. gon‐
dii is an obligate intracellular protozoan parasite that infects approximately one-third of
the world’s population. In most immunocompetant individuals, the chronic infection is
asymptomatic due to an effective immune response that eliminates active parasite repli‐
cation. The parasite has evolved immune evasion strategies that enable it to survive and
persist long enough in the host however to establish a chronic infection in which the cyst
stage persists within neurons in the brain and skeletal muscle in the periphery. T. gondii
has evolved multiple mechanisms to resist killing by apoptotic, autophagic and necrotic
cell death pathways, and the parasite’s manipulation of host PCD pathways plays a cru‐
cial role in host–parasite interactions and maintenance of the chronic infection. While
most individuals chronically infected with T. gondii are asymptomatic, severe disease can
occur in immunocompromised individuals where the infection reactivates from the brain
causing severe necrotizing encephalitis, and increasing evidence indicates chronic cere‐
bral toxoplasmosis in some individuals may lead to neuropsychiatric disorders such as
schizophrenia and suicidal behavior. This review will focus on the role of PCD pathways
in host defense of T. gondii and the parasite manipulation of these PCD pathways. A bet‐
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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ter understanding of the molecular components underlying the PCD pathways and the
parasite manipulation of these pathways may yield new therapeutic targets for treatment
of clinical sequelae of cerebral toxoplasmosis.
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1. Introduction
Overview of Programmed Cell Death (PCD) pathways and applications to Toxoplasma
gondii infection
Programmed cell death (PCD) pathways are genetically programmed mechanisms that can
trigger the cell to die or commit “cell suicide”. There are three major forms of programmed
cell death which are now recognized: apoptosis (type I), autophagic cell death (type II) and
necrotic cell death or necroptosis (type III) [1–4]. Apoptosis, the best-characterized and
dominant form of PCD, is a controlled physiological process of cellular self-destruction that
removes dead cells without damage to the host. Apoptosis is critically important during
development and morphogenesis and eliminates damaged cells such as cancerous cells or
infected cells that may interfere with normal function. Necrosis, conversely, is a cell death
process that is observed in response to severe stresses such that occurs after physical injury or
prolonged ischemia and has been long thought to be an unregulated process. However, a
programmed form of necrotic death, called necroptosis, is now recognized that can occur
during physical traumas, in neurodegeneration, in cell death due to ischemia or infection and
that, in contrast to unordered necrosis, has dedicated molecular pathways controlling necrotic
cell death. Autophagy is predominantly a strategy for survival and not death, serving as a
housekeeping mechanism of normal turnover of long-lived proteins and whole organelles and
crucial to maintenance of healthy cells. However, autophagy can promote cell death during
normal development and excessive autophagy, stimulated in times of stress such as nutrient
deprivation and some diseases, can lead to what is now recognized as autophagic cell death
[5–7]. While these cell death processes were once thought to occupy discrete cell states,
evidence suggests apoptosis, autophagy and necroptosis are often regulated by similar
pathways, share initiator and effector molecules and some subcellular compartments indicat‐
ing a complex crosstalk exists between these three main forms of cell death pathways, resulting
in a balanced interplay by which the cell decides its fate [8].
PCD pathways are also an important part of host defense against intracellular pathogens. The
intracellular protozoal pathogen, Toxoplasma gondii, is a common infection that causes a chronic
infection of central nervous system that persists for the lifetime of the individual. PCD
pathways are a key part of the host defense against T. gondii, but the parasite has evolved
multiple mechanisms to resist killing by host cell death pathways. Parasite manipulations of
host cell death pathways are essential components leading to successful establishment of
infection and for maintenance of the chronic infection in the host. In this review, the molecular
components and signaling pathways of each of the three main types of PCD pathways will be
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discussed with the role of these PCDs in the pathogenesis of the intracellular pathogen, T.
gondii, and potential therapeutic targets for toxoplasmosis and other diseases, the focus of this
review.
2. Apoptosis, necroptosis and autophagic cell death pathways:
Morphological features and molecular components
Apoptosis, necroptosis and autophagic cell death pathways operate via distinct genetically
programmed molecular mechanisms containing dedicated molecular components and leading
to characteristic morphological features (Figure 1). Apoptosis operates via a caspase-depend‐
ent mechanism while necroptosis and autophagic cell death are caspase-independent proc‐
esses, with autophagic cell death being cathepsin-dependent and necroptosis mediated via the
receptor interacting protein kinase 3 (RIP3) and its substrate, the mixed lineage kinase-like
domain protein, MLKL [8]. Apoptosis results in mitochondrial membrane permeabilization,
chromatin condensation and DNA fragmentation, resulting in cells become smaller (pknotic)
and membrane blebbing into apoptotic bodies. Phagocytes, such as macrophages, subsequent‐
ly engulf apoptotic cells and hence apoptosis is considered a noninflammatory form of
programmed cell death. Necrotic cell death, in contrast to apoptosis, is marked by swelling of
ER and mitochondrial organelles, increase in cell size, rapid rupture of the plasma membrane
resulting in lysis of the cell and release of danger-associated molecular patterns (DAMPs)
which stimulate inflammation. While necrosis has traditionally been considered to be “patho‐
logical cell death”, necroptosis is now recognized to occur via a regulated mechanism that is
inhibited by caspases [9, 10]. Autophagy is the process by which cells recycle cellular constit‐
uents and involves engulfment of cytoplasmic material and intracellular organelles within
double-membrane vesicles called autophagosomes that fuse with lysosomes to make auto‐
phagolysosomes that degrade the cellular cargo via cathepsins located in the autolysosomes.
The molecular components and signaling pathways of each cell death processes are reviewed
below, followed by the current understanding of the crosstalk that exists between these PCD
pathways.
2.1. Apoptosis
The term apoptosis was first used in 1972 by Kerr, Wyllie and Currie [11] to describe a form
of cell death morphologically distinct from necrosis. Apoptosis has since been well studied
and is now understood to be a regulated energy-dependent process mediated via cysteine-
dependent aspartate-directed enzymes called caspases [3]. Apoptosis is a homeostatic process
that balances cell numbers and plays a crucial role in several physiological processes including
embryogenesis to shape morphological structures such as fingers, in the establishment of
functional synaptic connections in the nervous system, in development of the immune
response to remove self-reactive lymphocytes and at the termination of the immune response
to remove antigen-specific lymphocytes. Apoptosis is also used to rid the body of cells in
various pathological conditions such as removal of cancerous cells, infected cells or cells
damaged by noxious agents [12].
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2.1.1. Signaling pathways and molecular components of apoptosis
Apoptosis is mediated via caspases which are present in the cytoplasm as pro-enzymes and
when activated initiate a proteolytic cascade that results in apoptosis of the cell. There are three
activation pathways that can initiate apoptosis: the extrinsic (death receptor) pathway, the
intrinsic (mitochondrial) pathway and the granzyme pathway (Figure 2). There are about 14
known caspases which are divided into initiator and effector caspases. Initiator caspases,
caspases 8, 9 and 10, are triggered by either the extrinsic, intrinsic or granzyme pathway,
respectively. All three pathways converge on caspase 3, which activates effector caspases 6
and 7 that lead to apoptosis. A major target of effector caspases is poly-ADP-ribose polymerase
(PARP) which is involved in DNA repair, cell survival, proliferation and differentiation.
The extrinsic pathway is initiated by binding of cell membrane receptors of Fas (CD95) or
tumor necrosis factor (TNF) family receptor (TNFR), which after binding its relevant ligand of
FasL or TNFα, respectively, trimerizes and attracts the docking proteins Fas-associated death
domain (FADD) and TNF receptor-associated death domain (TRADD), respectively. FADD
Figure 1. Comparison of three types of Programmed Cell (PCD) Pathways. The molecular mechanisms and morpho‐
logical characteristics of Apoptosis, Autophagic Cell Death and Necroptosis cell death pathways, so-called PCD types
I, II and III, respectively, are indicated. RIP3 = receptor-interacting protein kinase 3; MLKL = mixed lineage kinase-like
domain protein
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contains two death effector domains that can bind and cleave caspase 8. TRADD lacks death
effector domains but binds FADD that then cleaves caspase 8. Activated caspase 8 then
activates caspase 3. The intrinsic pathway is activated via changes in the mitochondria
membrane potential which can be triggered via stress, toxic reagents, UV irradiation and
inflammation. Changes in mitochondria membrane result in translocation of cytochrome c
from the inner mitochondrial membrane into the cytoplasm. Cytochrome c binds to apoptosis
protease activating factor 1 (APAF-1) which in the presence of ATP cleaves caspase 9. The
intrinsic pathway is regulated by Bcl-2 which localizes to the outer mitochondria membrane.
Bcl-2 members (Bcl-2 and Bcl-x) are anti-apoptotic while others such as Bax and Bad are pro-
Figure 2. Signaling Pathways of Apoptosis. Apoptosis is induced through either the extrinsic pathway (A), intrinsic
pathway (B) or the granzyme pathway (C). Activation of initiator caspases 8 and 9 (Casp 8,-Casp9), leads to apoptotic
cell death through activation of Caspase 3 (Casp3) and subsequent activation of effector caspases 6 and 7 (Casp 6-
Casp7). The extrinsic pathway (A) is initiated via extracellular molecules, FasL and TNFα, which bind to TNFR family
members, Fas and TNFR respectively which activate Casp8 (green lines). The intrinsic pathway (B) is initiated by
stress, UV irradiation and inflammation which act on the mitochondria through the pro-apoptotic Bcl-2 family mem‐
bers, such as Bax, resulting in the blockage of the anti-apoptotic activity of Bcl-2 (red lines). As a result, Cytochrome c
is released into the cytoplasm and activates Casp9 through APAF-1 (green lines). Casp8 may also trigger the intrinsic
pathway through activation of Bid, which inhibits the anti-apoptotic activity of Bcl-2. The granzyme pathway (C) is
activated via cytotoxic T cells (CTLs) that introduce granzyme molecules into the target cells via secretion of perforin,
which through a multimerization process forms a pore in the cell membrane allowing granzyme into the target cell.
Granzymes cleave multiple caspases, including Caspase 10.
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apoptotic. The granzyme activation pathway is stimulated by cytotoxic T lymphocytes (CTLs)
or NK cell secretion of perforin, which creates pores in the target cell membrane allowing
granzymes into the cytoplasm activating caspase 10 which can then activate caspase 3.
2.1.2. Apoptosis in physiological and pathological conditions and potential therapeutic application
Apoptosis is a tightly regulated process and is rarely observed in healthy animals because
phagocytes rapidly remove apoptotic cells. Abnormalities in cell death regulation can be a
significant component of diseases such as cancer, AIDS and neurodegenerative diseases such
as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and amyotrophic lateral
sclerosis. Some of these conditions are characterized by insufficient apoptosis and others
excessive apoptosis. Excessive apoptosis, for example, is a feature of neurodegenerative
diseases while resistance to apoptosis characterizes many cancers. Understanding the mech‐
anisms of apoptosis at the molecular level may provide therapeutic interventions in these
diverse disease processes.
2.1.2.1. Autophagic cell death
Autophagy, which means literally to “eat oneself”, is a physiological response to stress such
as starvation and is considered the major cellular mechanism for generating the needed
metabolic sources of energy and metabolites during times of nutrient deprivation. Autophagy
can also be used to remove damaged or unwanted organelles, such as mitochondria and long-
lived proteins. Autophagy is a homeostatic mechanism that is predominantly a cytoprotective
process [7, 13]. Other substrates are also now recognized as potential cargo for autophagy
including lipids, nucleic acids, reticulocytes and intracellular pathogens and viruses. The
concept of autophagic cell death has been a matter of debate, but it is now recognized as a type
of programmed cell death mechanism that can lead to both apoptotic and necrotic cell death
in certain circumstances such as extreme stress conditions [14, 15]. Autophagic cell death or
type II programmed cell death is now used to refer to cell death process distinct from apoptosis
that is caspase-independent and occurs with accumulation of double-membrane organelles
called autophagosomes.
2.1.3. Signaling pathways and molecular components of autophagy
Autophagy delivers cytosolic materials to the interior of the lysosomes for degradation via a
process involving the “de novo” formation of cytoplasmic double-membrane vacuoles called
autophagosomes which then fuse with lysosomes forming an autolysosome that degrades the
cellular cargo (Figure 3). Autophagy is regulated by a genetic program with a number of
autophagy-related genes (Atg) whose gene products (ATG proteins) regulate distinct steps in
autophagy. The autophagic pathway proceeds through the following defined steps: (i)
initiation phase involves the formation of an isolation membrane or phagophore, (ii) elonga‐
tion of the phagophore, (iii) maturation of an autophagosome with accumulation of cytosolic
cargo, (iv) fusion of the mature autophagosome with the lysosome and (v) degradation of the
contents via lysosomal proteases (i.e., cathepsins) in the autolysosome. The initiation phase
involves formation of an initiation complex comprised of the class III PI3 kinase, VSP34, which
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converts phosphatidylinositol to phosphatylinositol-3-phosphate (PI3P). The activity of
VSP34, which binds to beclin 1, requires the activity of VSP15, the regulator beclin 1 and
ATG14L (Figure 3a). Elongation of the autophagosome membrane requires action of two
ubiquitin-like conjugation systems, the Atg5–Atg12 conjugation system and the microtubule-
associated protein-1 light chain (LC3). The phosphatidylethanolamine-conjugated form of
LC3, LC3-PE (also called LC-II) is generated by ATG4-dependent proteolytic cleavage of LC3
and the action of the E1 ligase, ATG7, the E2 ligase, ATG3 and the E3 ligase complex, ATG12/
ATG5/ATG16L. LC3-PE stably associates with the autophagosome and is commonly used as
a marker for autophagosomes.
Figure 3. Autophagy Pathway. Autophagy is a membrane-dependent pathway that involves a series of defined steps
beginning with a nucleation step which then leads to: 1). Initiation of the isolation membrane or phagophore, 2). For‐
mation of the autophagosome around cellular cargo, 3). Fusion of autophagosome with lysosomes, and 4). Degrada‐
tion of cargo by lysosomal proteases in autolysosomes. Formation of the initiation complex (also called Class III PI3K
Complex) as shown in Figure 3a, consists of Beclin-1, ATG14L, VPS34 and VPS15. Activation of the initiation complex
requires disruption of binding of Bcl-2 to Beclin-1. The Class III PI3K complex generates PI3P at the site of nucleation
of the isolation membrane, which leads to binding of PI3P-binding proteins and the subsequent recruitment of pro‐
teins involved in the ‘elongation reaction’ of the isolation membrane. These proteins contribute to membrane expan‐
sion resulting in the formation of a double-membrane structure, the autophagosome that surrounds cellular cargo. The
phosphatidylethanolamine-conjugated form of the LC3 (LC3-PE) is generated by the ATG4 dependent proteolytic
cleavage of LC3 and the action of E1 ligase, E2 ligase and the E3 ligase ATG12/ATG5/ATG16L. LC3-PE stably asso‐
ciates with the autophagosome and is a marker of autophagosomes and therefore LC3 is commonly used as a marker
of autophagy pathway.
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While the autophagy pathway is primarily a homeostatic process promoting cell survival,
increased autophagosomal formation can occur coincidentally with cell dying indicating
autophagy may be involved in regulated cell death pathways, most notably apoptosis [7, 13].
For example, in apoptosis-comprised cells, cells die via a caspase-independent mechanism
characterized by autophagosome accumulation, implicating a role for autophagy in the cell
death process. Autophagy and apoptosis may also be regulated coordinately as anti-apoptotic
proteins that downregulate apoptosis can also downregulate autophagy. For example,
members of the Bcl-2 family can bind to beclin-1, thus inhibiting the formation of initiation
complex that is necessary to stimulate autophagy. Other studies indicate once apoptosis is
activated, apoptosis effector molecules may suppress autophagy as beclin-1 is cleaved and
inactivated by caspases. Finally, studies also indicate autophagy proteins may play a dual role
in regulation of apoptosis and autophagy. For example, Atg5 may affect the extrinsic apoptotic
pathway through interaction with FADD proteins, while Atg12 is an effector of intrinsic
apoptotic pathway with both Atg5 and Atg12 acting as pro-apoptotic regulators.
Autophagy pathway has also been implicated in necrosis and necroptosis cell death. Evidence
indicates autophagy may be able to act as an inhibitor of necrosis/necroptosis by preserving
cellular functions, removing toxic products and maintaining cellular energy. For example,
knockdown studies of components of autophagy pathways, such as beclin-1, have found
cytotoxicity is exacerbated suggesting that autophagy has a cytoprotective role. Autophagy
may be able to act as a buffer to metabolic stress, providing a mechanism to generate ATP to
maintain metabolic viability and thus prevent necrotic cell death. Conversely, studies using a
specific inhibitor of necroptosis, necrostatin-1, found both necroptosis and autophagy were
inhibited, indicating autophagy may be induced by necrosis. Molecular components under‐
lying the relationship between autophagy and necroptosis/necrotic cell death at this point are
poorly understood.
2.1.4. Physiological and pathological roles of autophagic cell death and therapeutic implications
Thus, while autophagy is now recognized to play a role in apoptotic and necrotic cell death
programs, this process is complex and incompletely understood. However, increasing
evidence indicates autophagic cell death may be necessary for cell death in certain circum‐
stances. It has been suggested autophagic cell death represents a failed adaptive mechanism
that may have prevented death under milder conditions. Understanding of the relationships
of autophagic cell death with other programmed cell death modalities will require further
study. The study of autophagy in disease is an emerging area of research. Autophagy pathway
and/or autophagic cell death pathways which result in failure to remove damaged organelles
and/or damaged cells are now thought to contribute to various diseases such as cancer,
neurodegenerative diseases such as Parkinson’s disease, aging and inflammation. Elucidation
of the influence of autophagy with other cell death programs will be essential to the develop‐
ment of therapeutics targeting autophagy for treatment of these various diseases. In the context
of infectious disease, autophagy also is now recognized to play an important role in intracel‐
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lular pathogen defense, and it has been suggested that intracellular pathogen load could be a
factor that disrupts the balance between cell survival and cell death [16].
2.2. Necroptosis
Pathologists first used the term “necrosis” in the early 19th century to describe tissue destruc‐
tion. Necrosis is characterized by organelle swelling and cell lysis, releasing the cellular content
of cells and resulting in inflammation. The first indication that necrosis could occur in a
regulated manner arose from observation that tumor necrosis factor (TNFα) could trigger
apoptosis and necrotic forms of cell death. Caspase inhibition strongly exacerbates necrotic
cell death, indicating caspase activity negatively regulates necrosis. This accumulating
evidence led to the concept of “programmed necrosis” and the coining of the term necroptosis
in 2005 to designate regulated necrotic cell death [4, 9]. Receptor-interacting protein kinase 3
(RIP3) and its substrate, the mixed lineage kinase-like domain protein (MLKL), are now
recognized as the key activation steps and the molecular hallmarks of regulated necrotic cell
death or necroptosis.
2.2.1. Signaling and molecular components of necroptosis
Programmed necrotic cell death can be activated when cells are stimulated by ligation of death
receptors including CD95 (also known as FAS), TNF receptors (TNFRs) and TNF-related
apoptosis-inducing ligand (TRAIL). Ligation of cell death receptors leads to the formation of
complex 1, comprised of TNFR-associated death domain protein (TRADD), TNFR-associated
factor 2 (TRAF2), receptor-interacting kinase 1(RIP1) and cellular inhibitors of apoptosis
(CIAPs) (Figure 4). Upon the release of second mitochondria-derived activator of caspases
(Smac) from the mitochondria, RIP1 is de-ubiquinated and dissociates from the death receptor
and induces the formation of FADD-RIP1-caspase 8 pro-apoptosis complex II. Conversion of
complex 1 to complex II indicates a change in cell fate from pro-survival to cell death. When
caspase 8 is inhibited, RIP1 and RIP3 form the necrotic death domain complex, the necrosome,
and their kinase activities become activated. RIP3 recruits it substrate monomeric MLKL from
the cytoplasm and phosphorylates it. The phosphorylation destabilizes MLKL and drives its
oligomerization which enables it to bind to phosphatidylinositol phosphate lipids (PIPs) and
cariolipin (CL). Different PIPs and CLs orchestrate the translocation of MLKL to different
membrane compartments including the mitochondria, endoplasmic reticulum, the Golgi,
lysosomes and plasma membranes. In addition to activation via death receptors, it is also now
clear that necroptosis can also be initiated by pathogen recognition receptors (PRRs) such as
toll-like receptors (TLRs) and cytokines via activation of RIP3 through distinct upstream
mechanisms.
2.2.2. Physiological and pathological roles of necroptosis and potential therapeutic applications
Programmed necrosis has been found to be important in host antiviral responses and a variety
of tissue-damage related diseases such as acute pancreatitis, ischemic reperfusion injury,
retinal detachment, atherosclerosis, neuronal loss in Gaucher’s disease, amongst others. It has
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been a paradigm that apoptotic cell death is anti-inflammatory with dead cells cleared by
phagocytes while necrotic cell death leads to inflammation and tissue damage. Necrotic cells,
however, can be internalized by macrophages although via macropinocytosis and thus in a
manner distinct from phagocytosis of apoptotic cells, but they are nonetheless efficiently
cleared by professional and nonprofessional phagocytes and hence rarely found in tissues.
Large numbers of dying cells such as may occur in excessive tissue injury, autoimmune
diseases such as systemic lupus erythematosus or infectious disease may lead to the defective
clearance of necrotic cells and contribute to the persistent inflammation and tissue damage.
However, smaller number of cells dying via necrosis or necroptosis may not necessarily lead
to massive tissue damage and hence controlled necrotic cell death may not necessarily lead to
massive tissue damage commonly associated with necrotic cell death.
Figure 4. Necroptosis Signaling Pathway. Ligation of tumor-necrosis factor 1 (TNFR1) leads to the formation of Com‐
plex 1 that is comprised of TNFR-1, TFNR1-associated death domain (TRADD), TNFR-associated factor 2 (TRAF-2),
Receptor-interacting kinase 1 (RIP1) and cellular inhibitors of apoptosis (CIAPs). RIP1 is initially modified by ubiquitin
chains within Complex I after recruitment to the membrane and serves as the signaling platform for NF-κB activation.
Upon release of the second mitochondria-derived activation of caspases (Smac) from the mitochondria, CIAPs are au‐
to-degraded. RIP1 is subsequently de-ubiquinated by CYLD and dissociates from the death receptor, and associates
with FADD-RIP1-Caspase8 forming Complex II, which is pro-apoptotic. Within Complex II, Caspase 8 activates Cas‐
pase 3/7 to induce apoptosis and blocks necrosis by cleaving and inactivating RIP1 and RIP3. When apoptosis is inhib‐
ited, as for example by Z-VAD, RIP1 and RIP3 form the necrotic death complex, the necrosome, and their kinase
activities become activated. RIP3 recruits the mixed lineage kinase domain-like protein, MLKL, and phosphorylates
MLKL, causing its activation. Activated MLKL then associates with membranes such as the plasma membrane, mito‐
chondrial members and others, causing lysis of these membranes and death of the cell. Inhibitors of necroptosis in‐
clude, Necrostatin 1 (Nec1) which inhibits RIP1 dependent necrosis by inhibiting the kinase activity of RIP1 to prevent
necrosome formation and Necrosulfonamide (NSA), which inhibits MLKL-mediated necrosis.
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Knockout of either RIP3 or MLKL genes in mice has been used to assess the physiological and
pathological roles of programmed necrosis. These types of studies have confirmed that
necroptosis is important in host antiviral responses and in some tissue-damage related
diseases. Several inhibitors have been identified that can inhibit necroptosis. Necrostatins, for
example, are small molecules that inhibit RIP1 kinase activity and thus inhibit necroptosis
(Figure 4). RIP1 also contributes to other processes such as apoptosis and NK-kB activation,
however, indicating other processes may also be affected by Nec-1. Targeting RIP3 or MLKL
offer more specific inhibitors for study or treatment of necroptosis. A chemical inhibitor of
MLKL called necrosulfonamide (NSA), for example, blocks necrosis by preventing oligome‐
rization of MLKL and thus is a specific inhibitor of necroptosis (Figure 4). Use of these specific
inhibitors of necroptosis will be essential to elucidate the role of necroptosis in cell death. As
the role of programmed necrotic death is now known to occur in several human diseases,
development of specific inhibitors of neroptosis could also have therapeutic uses.
2.3. Crosstalk between apoptosis, necroptosis and autophagy PCD pathways
As molecular components and regulation of each pathway has become better understood,
it has become apparent that significant crosstalk exists between the three major pathways
of  programmed  cell  death,  the  focus  of  which  has  been  the  topic  of  several  recent  re‐
views [3, 8, 10, 13]. Extensive crosstalk exists between apoptosis and autophagy as discussed
above in the section on autophagic cell death. The stimuli for apoptosis and autophagy are
often the same and evidence indicates instances where they can cooperate, antagonize or
assist  each  other.  Caspases,  Beclin-1  and/or  the  TOR  kinase  pathway  have  all  been
implicated  in  participating  in  the  complex  crosstalk  between  apoptosis  and  autophagy.
Crosstalk between apoptosis and necrosis also appears to exist as receptors that stimulate
apoptosis  can  also  stimulate  necroptosis.  Energy  is  thought  to  play  a  central  role  in
determining the interplay between these two pathways where instances of high ATP levels
would enable a cell to undergo apoptosis while low ATP levels would favor necrosis. Other
factors such as p53, Bcl-2 proteins and PARP1 are also suggested to play a role. Evidence
also  suggests  a  complex  interplay  between autophagy and necroptosis.  Autophagy and
necrosis can be activated in parallel  or sequentially and can have either opposite or the
same effects.  Autophagy, for example, can protect against some types of necroptotic cell
death with autophagy serving as the last resort before cell death via necrosis. The molecu‐
lar  basis  for  interlinked  processes  in  autophagy  and  necroptosis  and  the  impact  of
autophagy on necroptosis  and other cell  death pathways [13],  however,  remain unclear.
While the molecular details are not fully understood, it  is clear that a complex crosstalk
and molecular interplay between apoptosis,  autophagy and necroptosis occur and deter‐
mine the ultimate fate of the cell to survive or die in a given situation or under a given
stress signal. A better understanding of the mechanisms of apoptosis, autophagic cell death
and necroptosis  at  the  molecular  level  and the  crosstalk  between these  cell  death path‐
ways would provide a  deeper  insight  into different  disease processes  and may provide
novel therapeutic strategies.
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3. Toxoplasma gondii: Manipulation of programmed cell death pathways
and impact on host–parasite interactions and maintenance of chronic
infection
PCD can be important host cell defense mechanisms to eliminate intracellular pathogens.
Toxoplasma gondii is an obligate intracellular protozoan parasite that causes a chronic infection
with approximately one-third of the world’s population chronically infected, making T.
gondii one of the most prevalent human parasitic infections worldwide [17–19]. In humans,
infection with T. gondii is characterized by rapid parasite replication and dissemination
throughout the body with the parasite capable of infecting all types of nucleated cells. The
acute infection is followed by a chronic infection that lasts for the lifetime of the individual
with the parasite harbored within neurons in the brain and muscle tissue in intracellular cysts.
In most immunocompetant individuals, the infection is asymptomatic due to an effective
immune response that eliminates active parasite replication. In immunocompromised
individuals such as AIDS patients that are chronically infected, the parasite reactivates from
cysts in the brain leading to severe and potentially fatal encephalitis. The parasite can also be
transmitted transplacentally and can cause severe neurological complications to the fetus
including mental retardation, hydrocephaly and chorioretinitis which can reactivate through
the first two decades of life potentially leading to blindness. Finally, increasing evidence
indicates that in some immunocompetant individuals, chronic infection with T. gondii may
lead to development of serious psychiatric disorders such as schizophrenia or suicidal
tendencies [20–22].
While the host mounts an effective immune response against T. gondii, the parasite has evolved
immune evasion strategies that enable it to survive and persist long enough in the host to
establish the cyst stage of the infection that can persist for the lifetime of the host. PCD
pathways are a key part of the host defense against T. gondii, but the parasite has evolved
multiple mechanisms to manipulate these pathways. For example, the parasite induces
apoptosis in selected immune cell lineages, thus suppressing the host immune response and
helping to establish infection but the parasite also has multiple mechanisms to resist killing by
apoptotic and, to lesser degree, autophagic and necrotic cell death pathways in different host
cell types. Thus, parasite manipulations of host cell death pathways appear to be an essential
component to the successful establishment of infection and maintenance of the chronic
infection. A brief summary of the mechanisms by which the parasite manipulates these cell
death pathways is reviewed below followed by a discussion of the potential therapeutic
interventions.
3.1. Apoptosis
T. gondii has the ability to promote apoptosis of immune effector cells early after infection in
selected cell types. In murine models of toxoplasmosis, apoptosis of CD4+, CD8+ T cells, B
cells, NK cells and granulocytes is observed in the spleen early after infection [23]. Apoptosis
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in Peyer’s patch T cells in perorally infected mice has also been observed [24]. Acute infection
of Toxoplasma in both mice and humans induces a state of transient immunosuppression as
determined by decreased antibody and T lymphocyte responses. Triggering of apoptosis of T
cells and other immune effector cells by T. gondii may be one factor by which the parasite
restricts the immune response, thus allowing the establishment of infection. Induction of
apoptosis of immune effector cells may be somewhat parasite strain-dependent as, in murine
models, high levels of apoptosis in T cells was induced when mice were infected with virulent
RH strain while this phenomenon was not seen in mice infected with avirulent strains.
Inhibition of apoptosis by infection with T. gondii has been found to occur in a wide range of
cell types including macrophages and a wide variety of non-immune effector cells such as
fibroblasts, endothelial cells, muscle cells and astrocytes [23, 25, 26]. Infected host cells are
resistant to induction of apoptosis to a wide range of stimuli including CTL-mediated
cytotoxicity, irradiation, growth factor withdrawal, TNFα and several toxic reagents. Blockage
of apoptosis in host cells establishes an anti-apoptotic condition of the host cell and favors
parasite persistence. Neighboring uninfected cells are also rendered resistant to apoptosis.
Inhibition of host cell apoptosis of non-immune effector cells likely ensures the host cell stays
alive long enough to facilitate intracellular replication of the parasite in the tissues while
suppression of apoptosis of uninfected neighboring cell may help create a microenvironment
in different tissues in which the parasite can persist and replicate.
While blockage of apoptosis is known to occur in a wide variety of host cells, modulation of
apoptosis in cells of the central nervous system (CNS) is less well studied and results are
ambiguous. T. gondii can infect neurons, astrocytes and microglia supporting growth of the
rapidly replicating tachyzoite form while bradyzoite stage and cysts develop only in neurons
and astrocytes. In murine astrocytes, infection blocks apoptosis beginning at 6–24 h after
infection, allowing time for the parasite to replicate, egress and initiate infection of a new host
cell [26]. Thus, inhibition of apoptosis in astrocyte host cells may allow an increase in parasite
numbers in the brain and help establish the chronic infection in the brain. Conversely, several
studies indicate the parasite induced apoptosis in neurons. For example, tachyzoites induced
apoptosis in mouse brain cells in adult mice including in neurons [27, 28]. Likewise, in a murine
model of congenital toxoplasmosis, infection resulted in a decrease in neuron number and
markers of apoptosis were found indicating infection induced apoptosis in CNS tissues [29].
In murine neural stem cells, infection was also found to induce apoptosis although only
apoptosis of neighboring neurons were assessed in this study [30]. A study in murine brain
indicated infected neurons were resistant to apoptosis and apoptosis was only induced in the
uninfected neurons [31]. Microglia cells which are activated in the brains of mice infected with
T. gondii with toxoplasmic encephalitis produced nitric oxide (NO), which induces neuronal
apoptosis indicating activated microglia may be part of the mechanism leading to neuronal
loss of uninfected neurons [32]. Collectively, the above results are suggestive of a mechanism
in which Toxoplasma infection of neural tissues induces apoptosis of neurons, thus leading to
loss of neurons which could lead to neurological abnormalities. However, it is unclear if
apoptosis of infected neurons was induced or, alternatively, if infected neurons are resistant
to apoptosis. Suppression of apoptosis of infected neuronal cells may facilitate development
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of the cysts in neurons and allow persistence of the parasite in the brain. A better understanding
of parasite modulation of apoptosis in infected neurons is thus of importance. A better
understanding of the modulation of apoptosis in infected neurons could lead to the develop‐
ment of antiparasitic drugs and other therapeutic interventions to control and manage the
chronic phase of infection.
3.1.1. Parasite mechanisms modulating apoptosis
The parasite replicates within a membrane-bound compartment called the parasitophorous
vacuole (PV), and hence it is not in direct contact with the host cell cytoplasm and regulators
or effectors of apoptosis. However, parasite secretory molecules, which are either released into
the host cell at invasion, secreted across the PV membrane (PVM) or act at the PVM cytosolic
surface, have been identified which can modulate host cell apoptosis [25, 33]. These mecha‐
nisms are briefly summarized below.
3.1.2. Parasite mechanisms that stimulate apoptosis
Several mechanisms have been identified by which the parasite can stimulate apoptosis. In
parasite-infected murine macrophages, supernatants can induce apoptosis of neighboring
uninfected macrophages via nitric oxide [34]. Induction of apoptosis has also been found to
occur via nitric oxide secretion from activated microglia. Nitric oxide secretion from activated
microglia can lead to neuronal cell death and may be an important mechanism by which
infection leads to neuronal loss in the brain. The parasite secretory molecule, GRA1, has been
identified as capable of inducing apoptosis of infected monocytes and uninfected bystander
cells [35]. Secreted GRA1 from sites of ongoing T. gondii replication could also induce apoptosis
of monocytes recruited to the site of parasite replication. Given monocytes are essential to
control parasite replication at the site of primary infection, inhibition of apoptosis in monocytes
could serve to downregulate host responses early in infection, helping to establish the infection
in the host.
3.1.3. Parasite mechanisms that inhibit apoptosis
Multiple mechanisms have been identified by which the parasite can inhibit apoptosis [25].
Activation of NF-κB is a mechanism that inhibits apoptosis in fibroblasts and some other host
cells [36–38]. Early after infection, the parasite induces rapid translocation of host cell tran‐
scription factor, NF-kB, into the nucleus, which activates cell survival pathways and induction
of an anti-apoptotic state of the host cell. Nuclear translocation of NF-κB and subsequent gene
expression requires activity of the host IκB kinase (IKK). The activation of NF-κB was associ‐
ated with localization of phosphorylated IκBα subunits to the PVM that was mediated by a
parasite-derived IκB kinase (TgIKK). TgIKK is produced as the parasite replicates, and thus
allows for a continued phosphorylation of IκB and sustained inhibition of apoptosis. Thus, T.
gondii modulation of NF-κB gene expression and induction of anti-apoptotic state of the host
cell involves both the host cell IKK and TgIKK activity at different phases of infection. NF-kB
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activation has not been found to occur in infected macrophages. Rather in macrophages, T.
gondii, inhibits apoptosis by Gi-protein-mediated signaling, activating PI 3-kinase leading to
phosphorylation of protein kinase B (PKB/AKt) as an inhibitor of apoptosis [39]. A micro-RNA-
mediated mechanism has also recently been identified in macrophages that inhibited apoptosis
via a reduction in Bim, a pro-apoptotic effector of the Bcl-2 family [40]. Other mechanisms have
been identified in various cell types that can inhibit caspase cascade including blockage of
caspases 8 and 9 and 3, increased expression of anti-apoptotic molecules of the Bcl-2 family,
decreased activity of poly (ADP)-ribose polymerase and inhibition of granzymes [33, 41].
Only a few parasite proteins that modulate apoptosis have been identified. The parasite serine–
threonine phosphatase, called TgPP2C, was recently identified which downregulates apopto‐
sis in host cells [42]. TgPP2C is secreted into host cells from the PV and translocates to the host
cell nucleus and has been shown to regulate growth and survival of the parasite. Using a yeast
two-hybrid system, TgPP2C was found to interact with host cell protein, SSRP1 (structure-
specific recognition protein 1), which binds to DNA and regulates DNA repair genes. It is
speculated that SSRP1 might also be involved in expression of other genes involved in cell
survival and apoptosis. Identification of other parasite molecules by which the parasite
manipulates host cell apoptosis would facilitate a deeper understanding of host–parasite
relationship and may lead to development of new therapeutic targets and antiparasitic drugs.
3.1.4. Parasite modulation of apoptosis: significance to pathogenesis
In conclusion, T. gondii has the ability to both promote and inhibit apoptosis of its own host
cell and of uninfected neighboring cells by multiple mechanisms. The ability to modulate
apoptosis varies by host cell type, parasite load and parasite virulence. Manipulation of
apoptosis has been proposed to be crucial to promoting a stable parasite–host interaction and
allowing establishment of persistent infection [23]. The multitude of anti-apoptosis mechanism
that the parasite T. gondii employs is likely reflective of its status as an obligate intracellular
parasite and the essentiality of maintenance of host cell viability to sustain parasite replication
and survival. However, intracellular replication eventually leads to lysis of the host cell and
typically occurs between 48 and 72 h post-infection, a temporal scale similar to apoptosis.
Given the similar temporal scales of lytic death of the host cell and cell death by apoptosis, it
can be argued inhibition of apoptosis of the host cell is not necessary to allow for parasite
replication. However, as the parasite needs to obtain purine, cholesterol, tryptophan and other
components from the host cell, the parasite inhibition of host cell apoptosis may also serve to
maintain the host cell in a pro-survival state to enhance availability of host cell nutrients.
Inhibition of apoptosis may also be critical for the chronic phase of infection allowing differ‐
entiation of bradyzoites and development of the cyst stage in neurons. A better understanding
of manipulation of apoptosis by bradyzoites in host cells and, specifically in neurons, is of
great importance as the CNS is the compartment in which the parasite predominantly persists
in the chronic infection and the cause of serious clinical sequelae in the CNS of immunocom‐
promised individuals causing reactivated toxoplasmosis, in immature immune system of the
fetus and newborns causing congenital toxoplasmosis, and in immunocompetant individuals
possibly contributing to the development of serious neuropsychiatric disorders.




Autophagy has been found to play a role in host defense against many intracellular pathogens
as the autophagy pathway can degrade intracellular pathogens via autophagolysosomes
including T. gondii [16]. T. gondii replicates within a membrane compartment in the host cell
called the parasitophorous vacuole (PV) that is a non-fusogenic compartment and does not
fuse with cell lysosomes. However, the PV can be delivered to the lysosomes via autophagy-
mediated delivery in IFN-γ-activated macrophages resulting in killing of the parasite [43]. This
autophagic-mediated parasite killing is mediated by the immunity-related GTPases (IRGs)
which are stimulated by IFN-γ. Engagement of CD40 also has been found to induce killing of
T. gondii via autophagy in many nonhematopoetic cells including endothelial cells lines,
human and mouse retinal pigment epithelial cells as well as in hemopoietic cells such as
macrophages [44, 45].
Interestingly, in non-immune-stimulated cells, evidence indicates the parasite can use
autophagy to enhance its own survival. In the first 24 h after infection, host cell autophagy is
upregulated and the parasite uses autophagy to acquire host cell nutrients, while at 24–36 h
after infection when significant parasite replication has occurred, host cell autophagy is
suppressed [46, 47]. This biphasic response may be due to the crosstalk that exists between
apoptosis and autophagy. That is, inhibition of apoptosis occurs in infected cells during the
first 24 h after infection and as a result of crosstalk, it has been suggested that autophagy is
stimulated and then, vice versa, during the later stages of the intracellular infection cycle (> 24
h post-infection), as apoptosis inhibition wanes, suppression of autophagy increases. Thus,
regulation of host cell autophagy by the parasite may be part of a cell survival mechanism in
T. gondii infected host cells related to inhibition of apoptosis. Interestingly, parasite-mediated
activation of AKt signaling has recently been found to prevent autophagy degradation of the
parasite [48]. As AKt activation has also been linked to inhibition of apoptosis in T. gondii
infected cells, this event suggests AKt signaling may be a pathway by which the parasite can
regulate both host cell autophagy and apoptosis pathways [39, 48]. Dual manipulation of host
cell apoptosis and autophagy pathways indicates a fine level of control of host PCD pathways
by the parasite to promote parasite persistence in the host. Further work on the interplay
between apoptosis and autophagy and the parasite modulation of these two processes is
needed to further elucidate these mechanisms.
3.3. Necrotic cell death
A few in vitro studies have reported T. gondii inducing necrotic cell death of host cells [49–52].
In IFN-γ stimulated fibroblasts and astrocytes, infection with avirulent parasite strains of the
parasite, rather than stimulating autophagic-mediated mechanism of parasite killing, induces
disruption of the PV membrane via IRG proteins resulting in parasite death and subsequently
triggering of necrotic host cell death [50, 53]. This type of necrotic death of the host cells
involved killing of intracellular parasites and thus would promote host survival via elimina‐
tion of the parasite. In these experiments, the parasite was found to egress within hours after
infection, thus limiting replication in host cells which also would promote clearance of the
parasite by immune cells. Experiments have similarly found early egress of the parasites in
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IFN-γ-stimulated astrocytes, indicating this mechanism may also function in the brain to limit
parasite numbers and aid in elimination of the parasite [54].
Conversely, Toxoplasma-specific primed T cells were found to be able to induce rapid egress
of the parasite, causing necrotic cell death of host cells via ligation of the death receptor or
perforin, but as egress was rapid the intracellular parasites escaped killing [55]. These egressed
parasites were capable of infecting neighboring cells, thus suggesting that during Toxoplasma
infection of T cells, death receptor-and perforin-mediated parasite egress may contribute to
parasite dissemination of the parasite. Furthermore, as necrotic cell death induced by death
receptor or perforin-dependent parasite egress contributes to inflammatory processes, it could
also lead to further spread of the parasite due to infection of invading leukocytes. This process
may also contribute to the establishment of infection in the brain as infected leukocytes can
invade brain. Finally, death receptor-induced or perforin-mediated egress could be involved
during the reactivation of T. gondii in chronically infected individuals, leading to reinfection
of egressed parasites in the brain. Thus, parasite evasion of this cell death pathway may have
significant consequences on the clinical sequelae of the chronic infection in the brain. Experi‐
ments in fibroblasts found necrotic host cell death was not dependent on the necroptosis
mediator RIPK3 or caspases [52]. Further studies are needed to ascertain if necroptosis occurs
in other cell types that have been associated with necrotic-type cell death in T. gondii infected
cells.
4. Parasite manipulation of PCD pathways: Conclusions and potential
therapeutic implications
A better understanding of the mechanisms by which the parasite modulates apoptosis,
autophagic and necrotic host cell death pathways will enhance our understanding of the host/
parasite relationship in toxoplasmosis and may yield new therapeutic targets to treat patho‐
logical consequences of cerebral toxoplasmosis. For example, while the infection is asympto‐
matic in immunocompetant individuals, recent evidence indicates chronic infection may lead
to psychiatric and other neurological disorders in some individuals. Some of these effects may
be due to modifications of processes leading to cell death or resulting in dysregulated cell
death, resulting in reduction in CNS cell numbers and specifically of neurons. Conversely,
inhibition of apoptosis of astrocytes in the brain could be crucial for establishment of the
parasite in this compartment, while inhibition of apoptosis of infected neurons may be essential
for development of bradyzoite stage and thus crucial to long-term persistence of the parasite
in the brain. The evidence indicates the parasite can manipulate both host cell apoptosis and
autophagy pathways, indicating a sophisticated level of parasite control of host PCD pathways
and elucidation of the molecular details of these mechanisms could lead to new therapeutic
targets with which to control the infection. A better understanding of manipulation of
apoptosis and other cell death pathways in the brain cells such as microglia, astrocytes and
neurons is of particular importance. The identification of molecular components of PCD
pathways crucial to parasite–host interactions in chronic toxoplasmosis could lead to devel‐
opment of new antiparasitic drugs and/or yield new potential therapeutic targets to treat
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pathological consequences of chronic cerebral toxoplasmosis in immunocompetant individu‐
als and reactivated toxoplasmosis in immunosuppressed individuals. A similar harnessing of
apoptotic, autophagic and programmed necrosis cell death pathways has been proposed to
treat cancers, neurodegenerative disorders and other diseases, where PCD pathways have
been identified as involved in pathogenesis [56]. The dissection of the molecular mechanisms
by which T. gondii manipulates apoptosis and other cell death pathways thus could also serve
as a benefit to probe pathways in normal cells and in diseases in which apoptosis and other
cell death pathways play a central role.
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